Synthetic gene therapy of liver diseases
Eukarÿs develops a new type of safe and well-tolerated gene therapy that is entirely synthetic and based on a generic manufacturing process and the C3P3 artificial artificial expression system.
This novel type of gene therapy is designed to be safe, affective and well-tolerated. In addition, it is based on generic manufacturing process.
Eukarÿs is focusing on the development of a pipeline of treatments for severe rare monogenic and frequent multifactorial liver disorders.
EUK-LTR, our first gene therapy for the treatment of a severe multifactorial liver disorder, has gained extended proof of concept in the animal.
If you are interested in a collaboration in the field of gene therapy based on mRNA, please contact us.